Search Results

Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.

• Authors : Wong PC; Department of Thrombosis Research, Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA. ; Crain EJ

Subjects: Hemostasis*; Aspirin/Aspirin/Aspirin/*therapeutic use ; Factor Xa/Factor Xa/Factor Xa/*pharmacology

• Source: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2007 Aug; Vol. 24 (1), pp. 43-51. Date of Electronic Publication: 2007 Feb 24.Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print-Electronic Cited Medium: Print

Record details

Findings in Factor Xa Inhibitors Reported from University of Campania (Clinical Performance And Persistence on Dual Pathway Inhibition With Rivaroxaban And Aspirin in Real-world Setting).

• Source: Drug Week; 6/21/2024, p337-337, 1p

Record details

Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?

• Authors : Bala, Abiram; Murasko, Marlon J; Burk, David R

Subjects: THROMBOEMBOLISM prevention; WARFARIN; ANEMIA

• Source: Hip International; Sep2020, Vol. 30 Issue 5, p564-571, 8p

Record details

Increased Incidence of Bleeding and Wound Complications With Factor-Xa Inhibitors After Total Joint Arthroplasty.

• Authors : Garfinkel, Jonathan H.; Gladnick, Brian P.; Roland, Niama

• Source: Journal of Arthroplasty; Feb2018, Vol. 33 Issue 2, p533-536, 4p

Record details

Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry.

• Authors : Debus ES; Department of Vascular Medicine, Vascular Surgery, Angiology, Endovascular Therapy, University of Hamburg-Eppendorf, Hamburg, Germany. Electronic address: .; Aboyans V

Subjects: Peripheral Arterial Disease*/Peripheral Arterial Disease*/Peripheral Arterial Disease*/diagnosis ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/adverse effects ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage

• Source: European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2024 Dec; Vol. 68 (6), pp. 784-795. Publisher: Elsevier Country of Publication: England NLM ID: 9512728 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2165

Record details

In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA 2 DS 2 -VASc >4.

• Authors : Romiti GF; Sapienza-University of Rome, Rome, Italy (G.F.R.).; Talerico G

Subjects: Pyridones*/Pyridones*/Pyridones*/therapeutic use ; Pyridones*/Pyridones*/Pyridones*/adverse effects ; Aspirin*/Aspirin*/Aspirin*/therapeutic use

• Source: Annals of internal medicine [Ann Intern Med] 2024 Nov; Vol. 177 (11), pp. JC125. Date of Electronic Publication: 2024 Nov 05.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

[Dual pathway inhibition in peripheral arterial disease].

• Authors : Altamura V; U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.; Mureddu GF

Subjects: Peripheral Arterial Disease*/Peripheral Arterial Disease*/Peripheral Arterial Disease*/drug therapy ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/therapeutic use ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage

• Source: Giornale italiano di cardiologia (2006) [G Ital Cardiol (Rome)] 2024 Nov; Vol. 25 (11), pp. 783-791.Publisher: Il Pensiero Scientifico Editore Country of Publication: Italy NLM ID: 101263411 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Effectiveness of low-dose rivaroxaban in preventing recurrent major adverse cardiovascular events in coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.

• Authors : Al Hennawi H; Department of Internal Medicine, Jefferson Abington Hospital, Pennsylvania, USA.; Khan MK

Subjects: Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/adverse effects ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/therapeutic use

• Source: Coronary artery disease [Coron Artery Dis] 2024 Nov 01; Vol. 35 (7), pp. 614-621. Date of Electronic Publication: 2024 Sep 25.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9011445 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study.

• Authors : Wang Z; Department of Vascular Surgery, The Ninth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China. Electronic address: .; Sheng L

Subjects: Femoral Artery*/Femoral Artery*/Femoral Artery*/diagnostic imaging ; Femoral Artery*/Femoral Artery*/Femoral Artery*/physiopathology ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage

• Source: Annals of vascular surgery [Ann Vasc Surg] 2024 Nov; Vol. 108, pp. 338-345. Date of Electronic Publication: 2024 Jul 14.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8703941 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.

• Authors : Fanaroff AC; Penn Cardiovascular Outcomes, Quality and Evaluative Research Center, Leonard Davis Institute, and Cardiovascular Medicine Division, University of Pennsylvania, Philadelphia, PA.; Vora AN

Subjects: Pyridones*/Pyridones*/Pyridones*/therapeutic use ; Pyridones*/Pyridones*/Pyridones*/administration & dosage ; Pyrazoles*/Pyrazoles*/Pyrazoles*/therapeutic use

• Source: American heart journal [Am Heart J] 2025 Feb; Vol. 280, pp. 60-69. Date of Electronic Publication: 2024 Nov 17.Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6744

Record details